Alnylam Stock Leads 3 Growth Picks With Healthy Earnings Outlook

With inflation trends, growth signals and interest rate expectations shifting across major economies, many investors are looking for companies that analysts already expect to grow earnings while keeping balance sheets in reasonable shape. That is exactly what the Healthy high growth potential screener focuses on. It filters for stocks where analysts see strong earnings growth over the next 3 years and where financials pass key quality checks. In this article you will see three stocks from that screener and how they might fit into a portfolio that aims for growth potential while still considering financial resilience.

Alnylam Pharmaceuticals (ALNY)

Overview: Alnylam Pharmaceuticals develops and sells RNA interference based drugs that target specific genes to treat serious conditions such as hereditary amyloidosis, hypercholesterolemia, hemophilia, acute hepatic porphyria and primary hyperoxaluria, and it is also working on treatments in areas like hypertension, obesity, metabolic disease, bleeding disorders and neurodegenerative conditions including Alzheimer’s and Parkinson’s.

Market Cap: US$38.3b

Alnylam Pharmaceuticals stands out in this screener because it already has several commercial RNAi therapies on the market, generates multi billion dollar annual revenue and is now profitable, while still having a broad late stage and early stage pipeline across rare diseases, cardiometabolic conditions and neuroscience. Some analysts report expectations of strong earnings and revenue growth, and recent quarterly results show revenue in the billion dollar range with positive net income. At the same time, the company leans heavily on its TTR franchise and uses debt, which can magnify both return on equity and risk if pricing pressure or trial setbacks appear. The key consideration for you is how that balance of growth potential and concentration risk fits your own tolerance for volatility.

Alnylam Pharmaceuticals now has a multibillion-dollar revenue base. However, the real story may be how analyst expectations line up with that pipeline. Get the full context in the analyst forecasts for Alnylam Pharmaceuticals

Coursera (COUR)

Overview: Coursera runs a global online learning platform that offers short courses, certificates and full degrees in fields like business, technology and data science to individuals, companies, universities and governments.

Market Cap: US$1.77b

Coursera provides exposure to the shift toward online upskilling and job focused credentials, supported by demand for tech and AI related courses as well as partnerships with employers and universities. Analysts have published forecasts that indicate revenue and earnings growth over the coming years, and the Simply Wall St model indicates the stock trades below its estimated future cash flow value. At the same time, Coursera is still loss making, faces heavy competition and depends on external content partners, while shareholder dilution and a relatively new management team add execution risk. For readers who want to understand how these potential growth drivers and risks compare, the full analyst workup on Coursera provides more detail than headline metrics alone.

Coursera’s accelerating push into job focused online learning is easy to like. Yet the real story sits in the detailed growth and risk trade off inside the analysis report for Coursera

Allied Gold (TSX:AAUC)

Overview: Allied Gold is a Toronto based gold producer that explores and operates mines across Africa, with a focus on extracting gold and silver from large open pit assets such as its flagship Sadiola project in Mali.

Operations: Allied Gold generates its revenue from three main mines, with approximately $689.4m from Sadiola, $372.7m from Bonikro and $317.4m from Agbaou.

Market Cap: CA$3.0b

Allied Gold provides direct exposure to sizeable African gold production, supported by operational upgrades, mine expansions and an exploration budget intended to extend mine life and support future cash flow. Analysts currently model rapid growth in both earnings and revenue, along with a P/S below many peers. This suggests expectations may be conservative if projects like Kurmuk ramp up as planned. At the same time, the company is still loss making, carries higher cost operations and depends heavily on a small group of mines in higher risk jurisdictions. Insider selling and a relatively fresh board also add governance questions. The full narrative sets out how those potential upside drivers compare with the concentration, geopolitical and funding risks that investors may wish to weigh.

Allied Gold’s accelerating production story and analysts’ growth forecasts sit next to concentrated assets and higher risk regions. Get the full risk reward picture in the 3 key rewards and 1 important warning sign

The three stocks covered here are only a small sample. The full Healthy high growth potential screener surfaced 1,508 more companies with similarly compelling growth and balance sheet stories through the Healthy high growth potential screener. Use Simply Wall St to identify and analyze the specific catalysts and narratives that matter to you so you can focus on the highest conviction ideas for your portfolio.

Take Control of Your Investment Journey

If Allied Gold or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Beyond Today

Markets can move quickly and early momentum can slip away while stocks are still under the radar. Review these ideas while they may still be less widely followed.

• Target steady portfolio ballast and let the 8 dividend fortresses help you identify income opportunities.
• Explore structural demand in critical minerals and use the 8 top copper producer stocks to see which producers fit your criteria.
• Consider potential infrastructure-related themes and review the 35 power grid technology and infrastructure stocks to compare a range of grid-focused stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com